The reactive T cells then exit the skin, re-enter the lymphatic or vascular spaces, and recirculate or undergo the process of natural cell death. In CTCL, specific skin-homing T lymphocytes ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly half of patients in a case series.

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

It is being tested in clinical trials for cutaneous T-cell lymphoma (CTCL ... with key secondary endpoints including ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

FOXP3 + regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21 , 2512–2518 (2007). Article CAS PubMed Google Scholar ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in ...

T-cell lymphomas include a number of subtypes of T cell-derived non-Hodgkins's lymphoma, including cutaneous T-cell lymphoma ... for tumor expansion and survival, representing a new and promising ...

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...